Chronic pain and hemp: how many points did pain intensity decrease in studies

What do studies say about hemp in chronic pain?

They mention an improvement measured in fractions of a point, not a resolution of symptoms. Three independent reviews of randomized trials measured a decrease in pain intensity ranging from 0.23 to 1.59 points on a scale from 0 to 10, depending on the form of the preparation, along with a simultaneous increase in the frequency of adverse events.

The most recent of these was published in 2026 in the Annals of Internal Medicine (PMID:41429020). It gathered 25 short trials with placebo and 2303 participants, of which 64 percent were diagnosed with neuropathic pain. Oral preparations, synthetic or purified, with a predominance of tetrahydrocannabinol over cannabidiol, showed an improvement of 0.78 points. Extracts applied to the mucous membrane of the oral cavity, with a similar ratio of both compounds, yielded 0.54 points. Where the ratio was reversed, there might have been no result at all.

Two older reviews looked more broadly. A review with sequential analysis (PMID:36716312) included 65 randomized trials and 7017 participants, and for chronic pain calculated 0.43 points, with no impact on acute pain or cancer pain. A network meta-analysis from 2024 (PMID:38171632) placed hemp alongside opioids based on 90 studies. These works differ in questions and selection of preparations, so their results cannot be added together.

How significant is an improvement of 0.78 points on the pain scale?

Minor, and the authors themselves call it that. There is no agreed threshold for this scale; however, published estimates of the difference perceived by the patient range roughly between one and two points, which is above the value measured for two of the three studied forms of the preparation.

The range within one group of preparations can be greater than the distance from placebo. In the same review, nabilone reduced pain by 1.59 points, while dronabinol reduced it by 0.23 points, even though both contain only tetrahydrocannabinol and are administered orally. The first of these numbers is almost seven times greater than the second, so the statement that hemp helps with pain loses sight of what these measurements actually determine.

The following table links each number to the study model from which it originates. Without this context, a fraction of a point appears to be a more precise measurement than it actually is.

The row with the confidence interval requires a separate disclaimer. The authors of that review noted a high risk of systematic error in 59 out of 65 included trials and in all results. An improvement in sleep quality of 0.42 points was paired there with a lack of impact on quality of life, and evidence concerning sleep alone is collected in a separate text about sleep.

Do cannabis perform better than opioids?

No, but not worse either. A network meta-analysis from 2024 (PMID:38171632), based on 90 randomized studies with 22,028 participants observed from 28 to 180 days, did not show a clear advantage for either side. The comparison ended in a draw, not in favor of cannabis.

Evidence of moderate certainty indicated that opioids provide a slight improvement in pain compared to placebo, as well as in physical functioning and sleep quality. For cannabis, the same picture was based on evidence of low to moderate certainty. Neither showed superiority over placebo in social and emotional functioning, and there is likely no difference in physical functioning between them. The certainty of evidence speaks to how much further research might change the outcome, not the magnitude of the improvement itself.

A draw does not imply interchangeability. Both groups of medications have different risk profiles, different modes of administration, and different pathways of dependence, and the network meta-analysis compares trial results that mostly did not directly compare these medications with each other. The statement of superiority of one side over the other is not supported by numbers in either direction.

What do these reviews not resolve?

They do not resolve issues of long-term treatment, of dried flower described by strain name, or of what a single individual might experience. All three comparisons provide averages from trials lasting at most six months, and the best results were achieved with preparations with measured active substance content, which is something different than raw plant material from a pharmacy.

The authors of the latest of these reviews themselves describe the measured improvement as small, and the studies lasted from one month to six months, so they say nothing about long-term treatment. The comparison with opioids did not favor cannabis, only without a clear advantage for either side. None of these studies concerned a single strain of dried flower or the assortment of a Polish pharmacy, and the preparations that performed best in them were medications with established doses, not dried flower.

Closing these questions would require randomized trials conducted on the raw plant material itself, lasting longer than a year and with doses counted the same in each center. Such studies for the assortment of Polish pharmacies have not been published. Observations from clinical practice usually do not have a comparative group, so they only answer the question of who reaches for a prescription, not the question of treatment effectiveness.

What strain characteristics are important for chronic pain?

These studies indicate primarily the ratio of two compounds, not the strain name. Improvement was measured where tetrahydrocannabinol was clearly more abundant than cannabidiol. None of the three cited reviews examined terpenes as a separate variable, so there are no answers regarding the scent profile.

Pharmaceutical raw material is described by the declared content of active substances, given with the manufacturer's tolerance, not by the dose per administration. In the trials from which the above numbers come, preparations with measured doses were most often studied: oral or administered to the mucosa. Translating such a result to a flower heated in a home device is an assumption of the reader, not a conclusion from the study.

Between registered positions, the declared content of active substances and the terpene composition differ, and the databases describing this composition can be contradictory. The declaration itself is subject to the manufacturer's tolerance, so the same trade name from two suppliers can be a raw material of different potency. A separate study on neuropathic pain collects evidence for this narrower form of ailment, as it concerned most participants in the cited trials. The list of approved items in Poland is maintained by a summary of available strains.

How quickly does the effect start and how long does it last?

This is determined by the route of administration, not the name of the preparation. With inhalation, the effect appears within a few minutes and subsides before evening; after ingestion, one waits significantly longer, but the episode lasts a substantial part of the day. This difference is greater than any difference between items from the pharmacy.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

For chronic pain, this difference returns in another place. The reviews cited above studied oral preparations and those administered to the mucosa, which are routes with a slower onset and longer duration, so the inhalation course described above is not what was measured in those studies.

What does the doctor decide, and what does the patient decide?

The final word rests with the attending physician, as this raw material reaches the patient only with a prescription in the Rpw category. The patient is left with a description of the course of the ailment, reporting side effects, and a complete list of preparations taken daily. This mode of dispensing does not allow for independent selection of items from the list.

The decision about the form of the preparation, the route of administration, and the size of the dose arises from the diagnosis and what else the patient is taking. The reviews mentioned above do not provide a rule that could be applied to one person, as they provide average differences compared to placebo burdened with uncertainty, not a course of action. The pharmacist dispensing the raw material checks the correctness of the prescription, but does not change the choice of preparation.

The patient is left with self-observation, conducted in such a way that it can be shown in the office: noting the intensity of symptoms on the same scale, times of administration, and what happened over the rest of the day. The availability of individual items in pharmacies changes from month to month, so the question of a substitute returns to the person issuing the prescription. The same person decides on the continuation or interruption of treatment, based on what the patient recorded between visits.

What side effects have been reported with the use of cannabis for this indication?

Most commonly dizziness, drowsiness, and nausea. In a review from 2026, their frequency clearly increased in both groups of preparations that improved the pain outcome. The comparison with sequential analysis of frequency did not provide numbers, but noted a high risk of systematic error in 59 out of 65 included trials.

These symptoms are not a curiosity here, as they concern the same nervous system that the preparation is supposed to act on for pain relief. Adverse events were more frequent in the arms receiving the preparation than in the arms with placebo, and in the same schemes where improvement could be measured. Therefore, the balance of benefits and harms is determined within a single preparation, not between strain names.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

Frequently Asked Questions

Do cannabis treat chronic pain?

No. Reviews of studies indicate a reduction in pain intensity by an average of a fraction of a point on a scale from 0 to 10 in observations counted in weeks and months, not a resolution of symptoms or treatment of their cause.

By how many points does pain decrease in these studies?

From 0.23 points for dronabinol to 1.59 points for nabilone, with 0.78 points for oral preparations with a predominance of tetrahydrocannabinol and 0.54 points for extracts applied to the oral mucosa. All these values come from a review published in 2026.

Do hemp products work better than opioids?

No advantage has been shown on either side. A network meta-analysis of 90 studies with 22,028 participants found a similar, slight improvement compared to placebo for both groups of drugs, and there is likely no difference in physical performance between them.

Do the results of these studies pertain to pharmacy-grade dried flower?

Only indirectly. The studies examined measured-dose preparations, either oral or applied to the oral mucosa, not the flower described by strain name. None of the cited works included a single strain or the assortment of a Polish pharmacy.

How long did these studies last?

From one month to half a year in the 2026 review and from 28 to 180 days in the network meta-analysis. These works say nothing about the effects of use counted in years, as no one conducted observations that long.

Who decides on the choice of strain for chronic pain?

The attending physician, as dried flower is a pharmaceutical raw material dispensed by prescription in category Rpw. This text describes the state of evidence and is not therapeutic advice or an indication of any product.

Dried flower is a pharmaceutical raw material dispensed by prescription in category Rpw. The material is informational in nature and does not replace medical consultation nor encourage the use of anything. This entry is not a sales offer; the store category drought is managed by a separate page. Editorial text: redakcja ubucha.pl.